Invention Grant
- Patent Title: Binding agents binding to PD-L1 and CD137 and use thereof
-
Application No.: US17172694Application Date: 2021-02-10
-
Publication No.: US11459395B2Publication Date: 2022-10-04
- Inventor: Isil Altintas , David Satijn , Rik Rademaker , Paul Parren , Ugur Sahin , Friederike Gieseke , Alexander Muik , Christian Grunwitz , Edward Van den Brink , Dennis Verzijl
- Applicant: GENMAB A/S , BIONTECH SE
- Applicant Address: DK Copenhagen; DE Mainz
- Assignee: GENMAB A/S,BIONTECH SE
- Current Assignee: GENMAB A/S,BIONTECH SE
- Current Assignee Address: DK Copenhagen; DE Mainz
- Agency: Lathrop GPM LLP
- Agent James H. Velema, Esq.; James V. DeGiulio
- Priority: EPPCT/EP2017/069839 20170804,EPPCT/EP2018/052946 20180206
- Main IPC: C07K16/28
- IPC: C07K16/28
Abstract:
The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
Public/Granted literature
- US20210163616A1 BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF Public/Granted day:2021-06-03
Information query
